Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $56 million
Aytu, a pharmaceutical company with the EXXUA depression drug and ADHD and pediatric products, agreed to a cash tender offer of $2.70 per share.
- Target
- Aytu BioPharma
- Buyer
- Rosemont Pharmaceuticals Holdings
- Value
- $56 million
Aytu BioPharma agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings through a cash tender offer of $2.70 per share. The transaction is valued at approximately $56 million on a fully diluted basis and is expected to close by the end of calendar 2026, subject to customary closing conditions.
Aytu is a pharmaceutical company focused on medicines for complex central nervous system diseases. Its commercial portfolio includes EXXUA (gepirone) extended-release tablets for major depressive disorder, ADHD treatments and pediatric products. For the fiscal first quarter ended September 30, 2026, Aytu reported net revenue of $14.8 million, up 6.9%, and a net loss of $3.9 million.
Aytu did not hold a quarterly earnings call due to the pending transaction. The company's first-quarter results cited higher commercialization costs and merger-related legal and consulting fees.
Background
- Business
- Pharmaceutical company focused on complex central nervous system diseases, with the EXXUA depression drug and ADHD and pediatric products
- Deal type
- Strategic
Sources
- RTTNewsNov 17, 2026
- marketscreener.comNov 15, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.
Follow coverage. Copy a feed link into your feed reader.